Palbociclib After CDK and Endocrine Therapy (PACE)

NCT03147287 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Palbociclib
DRUG: Fulvestrant
DRUG: Avelumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]